CD4+ CAR-T Cell Exhaustion Associated with Early Relapse of Multiple Myeloma after BCMA CAR-T Cell Therapy

While there were no pre-existing T cell features associated with clinical outcomes, scientists found that patients with a durable response to CAR-T cell treatment had greater persistence of their CAR-T cells compared to patients with transient clinical responses.